693 related articles for article (PubMed ID: 33572196)
1. Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S; Labadie BW; Argulian A; Patnaik A
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33572196
[TBL] [Abstract][Full Text] [Related]
2. The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy.
O' Donovan DH; Mao Y; Mele DA
Curr Med Chem; 2020; 27(34):5654-5674. PubMed ID: 31250749
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
4. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.
Brown M
Cancer Treat Res; 2022; 183():91-129. PubMed ID: 35551657
[TBL] [Abstract][Full Text] [Related]
5. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway.
Ding C; Song Z; Shen A; Chen T; Zhang A
Acta Pharm Sin B; 2020 Dec; 10(12):2272-2298. PubMed ID: 33354501
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
8. Targeting the innate immune system with nanoparticles for cancer immunotherapy.
Li K; Zhang Z; Mei Y; Li M; Yang Q; Wu Q; Yang H; He L; Liu S
J Mater Chem B; 2022 Mar; 10(11):1709-1733. PubMed ID: 35179545
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
10. Innate Immune Receptors.
Muñoz-Wolf N; Lavelle EC
Methods Mol Biol; 2016; 1417():1-43. PubMed ID: 27221479
[TBL] [Abstract][Full Text] [Related]
11. Innate and intrinsic antiviral immunity in skin.
Kawamura T; Ogawa Y; Aoki R; Shimada S
J Dermatol Sci; 2014 Sep; 75(3):159-66. PubMed ID: 24928148
[TBL] [Abstract][Full Text] [Related]
12. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
Li K; Qu S; Chen X; Wu Q; Shi M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
[TBL] [Abstract][Full Text] [Related]
13. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
14. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
15. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
17. Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection.
Takahama S; Yamamoto T
Front Cell Infect Microbiol; 2020; 10():216. PubMed ID: 32457851
[TBL] [Abstract][Full Text] [Related]
18. Exploiting RIG-I-like receptor pathway for cancer immunotherapy.
Jiang Y; Zhang H; Wang J; Chen J; Guo Z; Liu Y; Hua H
J Hematol Oncol; 2023 Feb; 16(1):8. PubMed ID: 36755342
[TBL] [Abstract][Full Text] [Related]
19. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
20. The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation Against Cancer.
Iurescia S; Fioretti D; Rinaldi M
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33121210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
